Education
About Us
Working with TipRanks
Follow Us
Nanosonics Limited (NNCSF)
OTHER OTC:NNCSF
NNCSF Stock Chart & Stats
$2.32
$0.00(0.00%)
At close: 4:00 PM EST
$2.32
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$2.10 - $3.45
Previous CloseN/A
Volume26.00
Average Volume (3M)100.00
Market Cap
$729.43M
Enterprise Value$878.40M
Total Cash (Recent Filing)$159.83M
Total Debt (Recent Filing)$9.88M
Price to Earnings (P/E)53.3
Beta-0.08
Next Earnings
Sep 01, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding303,346,040
10 Day Avg. Volume70
30 Day Avg. Volume100
Financial Highlights & Ratios
PEG Ratio0.95
Price to Book (P/B)5.85
Price to Sales (P/S)6.18
P/FCF Ratio34.85
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue4.24
Enterprise Value/Gross Profit5.49
Enterprise Value/Ebitda30.22
Forecast
1Y Price Target
$2.98Price Target Upside28.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)0.04
Revenue Forecast (FY)$152.89M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue & Installed BaseNanosonics' recurring consumables and service growth (9% YoY) supported by a 6% larger installed base creates durable, usage-driven revenue. The razor-and-blades model yields predictable cash flows, high marginal economics and revenue resilience as device penetration expands in healthcare.
High Gross Margins & Improving ProfitabilityConsistently very high gross margins (~76–78%) and rising net margin reflect structural pricing power and low variable costs tied to consumable sales. Strong margins enable operating leverage, fund R&D and commercialization, and support long-term profitability through growth cycles.
Balance Sheet Strength And CashA debt-free balance sheet and ~A$160m cash position provide financial flexibility to fund CORIS commercialization, targeted investments and buybacks without refinancing risk. Low leverage increases resilience to shocks and supports multi-region scaling over the medium term.
Bears Say
FX Sensitivity To GuidanceMaterial international revenue exposure and explicit guidance sensitivity to AUD/USD mean currency swings can materially affect reported revenue and margins. Even with hedging, persistent FX volatility complicates multi-quarter forecasting, revenue visibility and capital allocation decisions.
Margin Pressure From Tariffs, Freight And MixExternal cost pressures (U.S. tariffs, higher air freight and adverse product mix) have already trimmed gross margin. If these structural cost items or unfavorable deal mix persist, they could limit operating leverage and constrain margin expansion despite revenue growth.
CORIS Commercialization Cost And Inventory BuildPreparing CORIS for regional commercialization requires elevated OpEx and inventory build before meaningful revenue arrives. This increases near-term cash usage and execution risk; delayed ramp or slower uptake would press margins and extend the payback period on commercialization investments.
Nanosonics Limited News
NNCSF FAQ
What was Nanosonics Limited’s price range in the past 12 months?
Nanosonics Limited lowest stock price was $2.10 and its highest was $3.45 in the past 12 months.
What is Nanosonics Limited’s market cap?
Nanosonics Limited’s market cap is $729.43M.
When is Nanosonics Limited’s upcoming earnings report date?
Nanosonics Limited’s upcoming earnings report date is Sep 01, 2026 which is in 182 days.
How were Nanosonics Limited’s earnings last quarter?
Nanosonics Limited released its earnings results on Feb 23, 2026. The company reported $0.022 earnings per share for the quarter, the consensus estimate of $0.022 by $0.
Is Nanosonics Limited overvalued?
According to Wall Street analysts Nanosonics Limited’s price is currently Undervalued.
Does Nanosonics Limited pay dividends?
Nanosonics Limited does not currently pay dividends.
What is Nanosonics Limited’s EPS estimate?
Nanosonics Limited’s EPS estimate is 0.02.
How many shares outstanding does Nanosonics Limited have?
Nanosonics Limited has 303,346,040 shares outstanding.
What happened to Nanosonics Limited’s price movement after its last earnings report?
Nanosonics Limited reported an EPS of $0.022 in its last earnings report, expectations of $0.022. Following the earnings report the stock price went down -8%.
Which hedge fund is a major shareholder of Nanosonics Limited?
Currently, no hedge funds are holding shares in NNCSF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nanosonics Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.98 (28.45% Upside)
$2.98 (28.45% Upside)
Blogger Sentiment
Bullish
NNCSF Sentiment 75%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $36.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
71.59%
12-Months-Change
Fundamentals
Return on Equity
10.32%
Trailing 12-Months
Asset Growth
11.93%
Trailing 12-Months
Company Description
Nanosonics Limited
Nanosonics Limited, together with its subsidiaries, operates as an infection prevention company in Australia and internationally. The company engages in the manufacturing and distribution of the trophon ultrasound probe disinfector, and its associated consumables and accessories; and research, development, and commercialization of infection control and decontamination products and related technologies. It provides trophon2, an ultrasound probe high level disinfection device; trophon EPR, a low temperature high level disinfection solution for intra-cavity ultrasound probes; and Nanosonics AuditPro, an infection control workflow compliance management solution. Nanosonics Limited was incorporated in 2000 and is headquartered in Macquarie Park, Australia.
NNCSF Company Deck
NNCSF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a substantially positive operational and financial picture: revenue and recurring revenue grew ~9% YoY, operating margin expanded materially (27%) with tight OpEx control, installed base and installations (20%) increased, and CORIS reached important regulatory and controlled release milestones. Headwinds cited were mostly external or transitional — FX volatility caused reported EBIT/PBT to dip slightly, gross margins were modestly compressed by tariffs, airfreight and product mix, and CORIS commercialization is driving incremental OpEx and near-term inventory investment. Overall, the company reaffirmed FY26 guidance (8–12% revenue growth at constant currency) and conveyed clear execution plans and balance-sheet strength, leaving the balance of information as net positive.View all NNCSF earnings summariesNNCSF Stock 12 Month Forecast
Average Price Target
$2.98
▲(28.45% Upside)
Technical Analysis
SDI Limited
―
Austco Healthcare Limited
―
Cyclopharm Limited
―
Trajan Group Holdings Ltd
―
Aroa Biosurgery Ltd
―
Ownership Overview
0.50% Insiders
3.11% Mutual Funds
0.03% Other Institutional Investors
93.49% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---